Analyst Price Targets — PRTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2025 10:38 am | Jason Butler | JMP Securities | $19.00 | $10.75 | TheFly | Prothena price target raised to $19 from $11 at Citizens JMP |
| December 1, 2025 9:32 am | — | Deutsche Bank | $19.00 | $10.75 | StreetInsider | Prothena Corp (PRTA) PT Raised to $19 at Citizens: Discovery Engine Successful |
| October 28, 2025 12:14 pm | Yasmeen Rahimi | Piper Sandler | $36.00 | $11.09 | StreetInsider | Prothena Corp (PRTA) PT Raised to $36 as Piper Sandler Remains Bullish |
| October 28, 2025 10:38 am | — | UBS | $36.00 | $11.31 | TheFly | Prothena price target raised to $36 from $15 at Piper Sandler |
| October 7, 2025 12:32 pm | — | H.C. Wainwright | $20.00 | $9.86 | TheFly | Prothena price target raised to $20 from $14 at H.C. Wainwright |
| September 2, 2025 10:36 am | Jason Butler | JMP Securities | $11.00 | $8.27 | TheFly | Prothena price target lowered to $11 from $29 at Citizens JMP |
| August 14, 2024 7:40 am | Jay Olson | Oppenheimer | $62.00 | $19.77 | StreetInsider | Prothena Corp (PRTA) PT Lowered to $62 at Oppenheimer |
| August 9, 2024 6:27 am | Kennen MacKay | RBC Capital | $24.00 | $19.68 | StreetInsider | Prothena Corp (PRTA) PT Lowered to $24 at RBC Capital |
| May 9, 2024 6:32 am | Kennen MacKay | RBC Capital | $28.00 | $23.03 | StreetInsider | Prothena Corp (PRTA) PT Lowered to $28 at RBC Capital |
| December 21, 2022 8:37 am | — | Cantor Fitzgerald | $98.00 | $58.98 | Benzinga | Cantor Fitzgerald Maintains Overweight on Prothena Corp, Raises Price Target to $98 |
Latest News for PRTA
Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines for key programs. PRTA's leading assets, prasinezumab (Parkinson's disease) and coramitug (ATTR-CM), are in phase 3 trials with primary completion expected in 2029. The Bristol-Myers Squibb partnership provides up to $1.55 billion in milestones and royalties, with BMS-986446 in phase 2 for early Alzheimer's.
The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company's outstanding shares.
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRTA.
U.S. House Trading
No House trades found for PRTA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.